This report delves into the challenges and potential solutions associated with flexible, customized subcutaneous immunoglobulin (SCIG) infusion regimens for patients with primary antibody deficiency disease (PAD). Advances in the treatment of inborn errors of immunity, particularly PAD, have converted fatal diseases into chronic, complex, long-term conditions that make adherence to treatment a critical issue. Conventional SCIG infusion regimens, while clinically effective, may not always align with the varied lifestyles, changing lifestyles and commitments of patients which can lead to missed doses, diminishing adherence thus posing potential health risks and compromising the overall effectiveness of treatment. For these reasons, it's important to develop flexible infusion regimens tailored to meet individual patient needs. Patient-centric strategies that promote shared decision-making and awareness of patient status not only promote medical efficacy but also enhance the overall patient experience. The authors of this report call attention for a need to shift toward more adaptable and individualized SCIG treatment plans for PAD patients whose needs may change over the long-term course of treatment.

Department of Clinical Immunology and Allergology St Anne's University in Brno Faculty of Medicine Masaryk University Brno Czechia

Division of Basic and Clinical Immunology University of California Irvine CA USA

Division of Pediatric Immunology and Allergy School of Medicine University of California Los Angeles CA USA

Medical Affairs Midland Pediatrics Papillion NE USA

Medical Affairs Octapharma AG Vienna Austria

Medical Affairs Octapharma USA Inc Paramus NJ USA

Citace poskytuje Crossref.org